PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE.
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2364
https://www.valueinhealthjournal.com/article/S1098-3015(19)34742-4/fulltext
Title :
PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE.
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34742-4&doi=10.1016/j.jval.2019.09.2364
First page :
Section Title :
Open access? :
No
Section Order :
12063